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ABSTRACT

A method of reducing corneal scarring or ?broblast prolif
eration comprises applying to an area of a subject’s eye
af?icted With the condition a corneal scar-?broblast
proliferation-reducing amount of a free or polymer-bound

HLE inhibitory agent under conditions and for a period of

Schmut, et al. BIOSIS Abstract No. 86:441139 1986.

time effective to attain the desired effect. A method of

Luce, J.M. Biol. Abstracts 81(3) AB—839. Abstract No.

reducing neovasculariZation of corneal scar tissue comprises

126950 (1985).
Chesnokova N. et al. Chem Abstracts v. 105, Abstract No.

applying to an area of a subject’s eye afflicted with the
condition a neovasculariZation-inhibitory amount of a free

131573y (1986).

or polymer-bound HLE inhibitory agent under conditions

Tuhy et al., “Inhibition of Human Leukocyte Elastase by

and for a period of time effective to attain the desired effect.

Peptide Chloromethyl Ketones,”, FEBS Letters, 50, 359—61

(1975).
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METHODS OF TREATING EYE
CONDITIONS WITH HUMAN LEUKOCYTE

thetic Elastase Inhibitor,” A. Janoff and R. Dearing, Am. J.

ELASTASE (HLE) INHIBITORY AGENTS

Respir. Dis., 121: 1025—3 (1980)). This is not surprising
since the alkylating moieties in these inhibitors might render

TECHNICAL FIELD

them toxic When used on a continuous basis. To be suitable
for human use, an enZyme inhibitor has to shoW a high

degree of selectively and must have minimal toxic side

This invention relates to methods of treating corneal

effects. As a result, most drugs are molecules that reversibly
bind to speci?c enZymes or receptor sites. Examples are the

scarring or ?broblast proliferation by applying to the ocular
area a human leukocyte elastase (HLE) inhibitory agent in a

prescribed amount.

10

BACKGROUND OF THE INVENTION

“The pharmacological Basis of Therapeutics”, p. 101, Mac

Proteinases from polymorphonuclear leukocytes and

Millan Publishing Co. (1980).

macrophages, especially elastases (human leukocyte
elastase and cathepsin G), appear to be responsible for the
chronic tissue destruction associated With in?ammation,
arthritis and emphysema. During infection or in?ammation

15

the normal lung is protected from proteolytic digestion by
the protease inhibitor al-antitrypsin. The protective mecha
nism appears to be non-operative in individuals With an
al-antitrypsin de?ciency due to genetic or other causes.

carbamate esters physostigmine and neostigmine Which
have been clinically used as inhibitors of acetyl choline
esteraces, A. G. Gilman, L. S. Goodman and A. Gilman,

20

A series of peptide elastase inhibitors Were disclosed in
US. Pat. No. 4,643,991 to Digenis et al. Another group of
polymer-bound elastase inhibitors Was disclosed in US.

application Ser. No. 242,294 by Digenis et al. ?led on Sep.
9, 1988, now US. Pat. No. 5,162,307, issued Nov. 10, 1992.
Still other peptidyl carbamate inhibitors of the enZyme
elastase Were disclosed in US. application Ser. No. 07/263,
385 entitled “Novel Peptidyl Carbamate Inhibitors of the

Synthetic elastase inhibitors capable of replacing

EnZyme Elastase” by Digenis et al., ?led on Oct. 27, 1988,

al-antitrypsin therefore appear to be useful in the treatment

now US. Pat. No. 5,008,245, issued Apr. 16, 1991. The

of pulmonary emphysema and related diseases.
Several types of elastase inhibitors have been reported in

25

the literature. These include peptide chloromethyl ketones as
described in “Inhibition of Human Leukocyte Elastase by

Peptide Chloromethyl Ketones”, P. M. Tuhy and J. C.
PoWers, FEBS Letters, 50, 359—61 (1975); “Speci?city of
Porcine Pancreatic Elastase, Human Leukocyte Elastase and
Cathepsin G. Inhibition With Peptide Chloromethyl
Ketones”, J. C. PoWers, B. F. Gupton, A. D. Harley, N.
Nishino and R. J. Whitley, Biochem. Biophys. Acta. 485,
156—66 (1977); aZapeptides “Proteinase Inhibitors. 1.
Inhibitors of Elastase”, C. P. Dorn, M. Zimmerman, S. S.
Yang, E. C. YureWicZ, B. M. Ashe, R. Frankshun and H.
Jones, J. Med. Chem., 20: 1464—68 (1977); “Reaction of
Serine Proteases With AZa-amino Acid and AZa-peptide
Derivatives”, J. C. PoWers and B. F. Gupton, Meth.

EnZymol., 46: 208—16 (1977); sulfonyl ?uorides “Speci?c
ity and Reactivity of Human Leukocyte Elastase, Porcine
Pancreatic Elastase, Human Granulocyte Cathepsin G, and
Bovine Pancreatic Elastase, Human Granulocyte Cathepsin

described therein. The contents of the Digenis et al patent
and applications referenced above are incorporated herein
by reference to the extent that they enable the speci?c HLE
inhibitory agents described therein and their methods of
30

and J. C. PoWers, J. Biol. Chem., 257, 5077—84 (1982-);
heterocyclic acrylating agents “Inhibition of Elastase and
Other Serine Proteases by Heterocyclic Acylating Agents”,
M. Zimmerman, H. Morman, D. Mulvey, H. Jones, R.

Various conditions of the eye are knoWn to be associated

cal injury, ocular infections such as kerato-conjunctivitis,
35

easily neovasculariZed and therefore becomes permanently
established and irrigated. Tissue scarring or ?broblast pro
40

steroids do increase side effects such as infection, cataract
45

tologie Der Crtisonkatarakt, p.327. Bergmann, Munich
Even after further surgery the proliferation of ?broblastic
50 tissue continues to occur and further scar tissue appears.

Thus, in addition to surgery being an extremely invasive
procedure, the results attained thereof are not entirely sat

isfactory.
Accordingly, there remains a need in the art for methods
55

of reducing and/or preventing the formation of corneal scar
tissue or ?broblast proliferation Which are not subject to the

disadvantages of methods knoWn in the art for this purpose.

60

SUMMARY OF THE INVENTION
This invention relates to a method of reducing corneal

scarring or ?broblast proliferation comprising applying to an
area of a subject’s eye af?icted With the condition a corneal
scar- or ?broblast proliferation-reducing amount of a human

leukocyte elastase (HLE) inhibitory agent under conditions

sema in animal models there is considerable question

Experimental Emphysema by Oral Administration of a Syn

and glaucoma. Other non-steroidal agents like indomethcin
have very little anti-scarring effects. (Williamson J. et al.,
British J. of Ophthalmology 53:361 (1969); Babel, J., His

(1973)).

Werner and F. Wold, Biochemistry, 16: 2492 (1977).
Although some peptide chloromethyl ketones have been
shoWn to be effective in preventing elastase induced emphy
Whether such reactive agents could be used for treating
emphysema in humans. (“Prevention of Elastase Induced

liferation is a condition Which is dif?cult to treat. Presently,
it is treated by subjecting the ocular area to further surgery

or by using steroids, topically or by injection. HoWever,

Commun., 95: 1890 (1980); and p-nitrophenyl-N alkyl
carbamates, “p-Nitrophenyl Carbamates as Active-Site
Speci?c Reagents for Serine Proteases”, R. E. Sco?eld, R. P.

and other ocular conditions. Some of these conditions are

knoWn to arise post-operatively after surgical treatment of
other ocular conditions. This undesirable tissue groWth is

Frankshun and B. M. Ashe, J. Biol. Chem., 255: 9848—51

(1980); “Selective Inhibition of Human Leukocyte Elastase
and Bovine ai-Chymotrypsin by Novel Heterocycles”, B. M.
Ashe, R. L. Clark, H. Jones and M. Zimmerman, J. Biol.
Chem., 256: 11603—6 (1981); imidaZole N-carboxamides,
W. C. Groutas, R. C. Badger, T. D. Ocain, D. Felker, J.
Frankson and M. Theodorakis, Biochem. Biphys. Res.

preparation.
With corneal scarring and ?broblast proliferation, amongst
them ocular coagulation and burns, mechanical and chemi

G, and Bovine Pancreatic Chymotrypsin With Arylsulfonyl
Fluorides”; “Discovery of a neW series of potent and speci?c
irreversible Elastase Inhibitors”, T. Yoshimura, L. N. Barker

latter Digenis application also provides methods of inhibit
ing the enZyme elastase With the peptidyl carbamate agents

65

and for a period of time effective to attain the desired effect.
Also part of this invention is a method of reducing

neovasculariZation of corneal scar tissue comprising apply

5,922,319
3

4

ing to an area of a subject’s eye af?icted With the condition
a neovasculariZation-inhibitory amount of an HLE inhibi

Which is not detrimental to the functions of the eye.

Typically, an aqueous solution of the HLE inhibitory agent
may be utiliZed. HoWever, given that some HLE inhibitory
agents are cleared very limpidly from the eye, they may also

tory agent under conditions and for a period of time effective
to attain the desired effect.

be bound to a Water soluble or hydrophilic polymer to ensure
a more prolonged residence in the desired area. The aqueous

A more complete appreciation of the invention and many

of the attendant advantages thereof Will be readily perceived

solution may also contain other ingredients as is knoWn in

as the same becomes better understood by reference to the

the art.

following detailed description When considered in connec

This invention thus provides a method of reducing corneal

tion With the accompanying ?gures.
10

scarring or ?broblast proliferation Which comprises apply
ing to an area of a subject’s eye af?icted With the condition

BRIEF DESCRIPTION OF THE DRAWINGS

a corneal scar- or ?broblast proliferation-reducing amount of

FIG. 1 is a print of a histological microscopic photograph
of a corneal tissue as described in Table 2. This photograph
shoWs a pathology section of an untreated corneal burn.

Excessive in?ammation and ?broblastic activity (thin

an HLE inhibitory agent under conditions and for a period
of time effective to attain the desired effect.
15

arroWs) can be seen. Severe neovascular formation is

inhibitory agents are knoWn in the art as discussed above and
need not be further described herein. By means of example,
inhibitory agents Which are suitable for use With this inven
tion are those described in US. Pat. No. 4,643,991 and US.
Pat. No. 5,008,245 both to Digenis et al. Aseries of peptide
elastase inhibitors Were disclosed in US. Pat. No. 4,643,991
to Digenis et al. These peptide elastase inhibitors are car

marked With thick short arroWs (H&E Stain x200).
FIG. 2 is a print of a histological microscopic photograph
of a corneal tissue described in Table 2. This photograph
shoWs a pathology section of a corneal burn treated With the
inhibitor of this invention. As can be seen, the degree of

in?ammation, scarring and neovascular formation is mini
mal and has been greatly reduced When compared With FIG.

1, the control eye (H&E Stain x200).

Any HLE inhibitory agent may be utiliZed When practic
ing the method of the invention. Typically, many HLE

bamates substituted by oligopeptides and may generally be
25

described by the folloWing general formula (I):

FIGS. 3, 5 and 7 are pathology sections of rabbit corneas
that Were thermally burned and treated for tWo Weeks With

(I)

polyvinyl alcohol. Severe in?ammatory reaction is seen

o

including formation of polymorphonuclear neutrophils,
eosinophils, ?broblasts, and granulation tissue (arroWs)
(HematoXylin and eosin x100).

R1

FIGS. 4, 6 and 8 shoW pathology sections of rabbit
corneas that Were thermally burned and treated With the
inhibitor of this invention for tWo Weeks. As can be seen, the

in?ammatory reaction is much reduced in comparison to the
control eyes (untreated) shoWn in FIGS. 3, 5 and 7.
In?ammation, scarring and neovasculariZation are much
reduced When compared With the control eyes (HematoXylin

35

group consisting of straight or secondary branched-chain
alkyl of 1 to 4 carbon atoms, alkenyl of 1 to 4 carbon atoms,
alkynyl of 2 to 4 carbon atoms, cycloalkyl of 3 to 6 carbon

and eosin x100).
Other objects, advantages and features of the present

atoms, preferably cyclopropyl or cycloheXyl, and benZyl,
and R is selected from the group consisting of substituted or
unsubstituted phenyl Wherein the substituents are selected

invention Will become apparent to those skilled in the art

from the folloWing discussion.
BEST MODE FOR CARRYING OUT THE
INVENTION

Wherein Z is selected from the group consisting of R“O-Suc
Where R“ is loWer alkyl of 1 to 3 carbon atoms and
CF3CO—; X is oXygen or sulfur, R‘ is selected from the

from the group consisting of nitro, preferably p-nitro, and

?uoro, preferably penta?uoro, benZyl, CH2CF2CF2CF3,
45

1-loWer alkyl tetraZolyl-, 1-phenyltetraZolyl-, 2-thioXo-3
thiaZolindyl, pyridyl, and benZothiaZolyl, provided that
When R is paranitrophenyl, R‘ is other than tertiary-butyl,
benZyl or cycloheXyl, and When X is sulfur, R is other than

This invention arose from a desire to improve over prior

art methods for treating ocular scarring or ?broblast
proliferation, particularly When it occurs in the cornea of the

benZyl.
In more preferred embodiments, the inhibitory peptides

eye.
The inventors have found for the ?rst time that if an HLE

may be described by the folloWing general formulae Ia or Ib:

inhibitory agent is applied to a subject’s eye it has an
inhibitory effect on the proliferation and groWth of ?bro

(Ia)

blasts or scar tissue. For the ?rst time the inventors have

shoWn that HLE inhibitors have an ophthomological appli
cation.
Thus, the present invention relies on the therapeutic
application of HLE inhibitory agents to the corneal area of
the eye to prevent and/or reduce corneal scarring or ?bro

O

55

Wherein X‘ is oXygen or sulfur and R2 is selected from the

blast proliferation as Well as neW vasculariZation. These

group consisting of phenyl, ?uorophenyl, nitrophenyl,
1-phenyltetraZolyl, 1-loWer alkyl tetraZolyl, benZyl,
3-thiaZolidinyl, pyridyl, and benZothiaZolyl, and R1 is

conditions have been found to be associated With a variety
of pathological states of the eye such as infections, burns and

mechanical and chemical injury, among others.
The inhibitory agents utiliZed in the present methods may

be applied to the eye topically, intraocularly, by injection or
through a contact lens. Preferred is topical. By means of
eXample the agents may be applied as a solution in a solvent

65

straight or secondary branch chained alkyl of 2 to 4 carbons,
alkenyl of 2 to 4 carbons, and alkynyl of 2 to 4 carbons,
provided that When R2 is p-nitrophenyl, R1 is other than
tertiary-butyl, and When X‘ is sulfur, R2 is other than benZyl;
and

5,922,319
6
(ii) a compound D of the formula:

(1b)
(D)
O

—O—Suc—Ala—Ala—Pro—CH2' N—("I—X2-R8

IL?

R3

Wherein
10

wherein Z‘ is selected from the group consisting of MeO
Suc-Ala-Ala and CF3CO-Ala-Ala, Wherein R3 is as de?ned

R8 is selected from the group consisting of phenyl,

for R1 above, but is preferably isopropyl.
However, other HLE inhibitory agents may also be uti
liZed for practicing the present method.
As already indicated above, the HLE inhibitory agents

15

R7 is selected from the group consisting of straight or

20

are suitable for practicing this invention. An eXample of the
group of polymer-bound elastase inhibitors useful in the
present invention, as disclosed in US. Pat. No. 5,162,307 to
Digenis et al., have the folloWing structures:
A Polymer of the formula

P—(L-R4)q

(iii) a compound E of the formula

(E)
25

30

Wherein
Z2 is —O—Suc-Ala-Ala:

(II)
35

Wherein P is a polymer comprising at least one unit of the

L is selected from the group consisting of a covalent bond
and a linker group Which is covalently bound to R4 and one

gradable and has an average molecular Weight of about
40

of A and B; and
q is about 1 to m+n.

More preferred compounds according to the Us. Pat. No.
5,162,307 are compounds Wherein

covalently binding to one of L and R4;
Wherein R4 is a compound selected from the group

consisting of

each said R4 being covalently bound to L or to one of A

and B,

formula (AmBn) Wherein (AmBn) is substantially nonbiode
1,000 to 500,000 daltons, m and n may be the same or
different and are about 5 to 3,000, and A and B may be the
same or different and at least one of A and B is capable of

that When R8 is p-nitrophenyl R7 is other than tertiary-butyl,
benZyl or cycloheXyl, and When X2 is sulfur R8 is other than

benZyl; and

Which does not detrimentally affect the function of the eye.
Many such polymers are knoWn in the art and discussed in
US. Pat. No. 5,162,307 to Digenis et al. The polymer-bound

HLE inhibitory agent described in the referenced application

nitrophenyl, ?uorophenyl, CH2CF2CF2CF3, 1-loWer
alkyltetraZolyl, 1-phenyltetraZolyl, benZyl, 2-thioXo-3
thiaXo-3-thiaZolidinyl, pyridyl and benZothiaZolyl, and

secondary branch chained (C1—C4) alkyl, (C2—C3) alkenyl,
(C2—C4) alkynyl, (C3—C6) cycloalkyl, and benZyl, provided

may be bound to a hydrophilic or Water-soluble polymer in
order to eXtend their residence in the area to Which they are

applied. The HLE inhibitory agents may be covalently
bound to any hydrophilic and/or Water-soluble polymer

X2 is O or S.

A is a compound of the formula
45

(i) a compound C of the formula

(Ila)
— HN — CH — (cH2)m2— co —

50

wherein
X1 is oxygen or sulfur;

55

CO

Wherein m2=0 or 1 and n2=1 or 0 respectively and R9 is

selected from the group consisting of OH, 2-hydroXyethyl

amine, 2-hdroXypropylamine, 3-hydroXypropyl amine, 2,3
dihydroXypropyl amine, 2-hydroXybutylamine and
4-hydroXybutylamine; and

R5 is selected from the group consisting of straight and

secondary branch-chained (C1—C4) alkyl, (C2—C3) alkenyl,
(C2—C4) alkynyl, (C3—C6) cycloalkyl, and benZyl; and
R6 is selected from the group consisting of substituted and
unsubstituted phenyl, Wherein the substituents are selected

(TI-12x12

60

B is a compound of the formula (Ila) above, Wherein R9
is selected from the group consisting of NH2, NH—NH2,

from the group consisting of nitro, and penta?uoro, benZyl,

NH—NH2, —NH—R1O—NH2 wherein R10 is (C2—C10)

CH2CF2CF2CF3, 1-loWer alkyl tetraZolyl,
1-phenyltetraZolyl, 2-thioXo-3-thiaZolidinyl, pyridyl and

(C2—C8) alkyl or (C6—C8) aryl.

benZothiaZolyl, provided that When R6 is p-nitrophenyl R5 is
other than tert-butyl, benZyl or cycloheXyl, and When X1 is
sulfur R6 is other than benZyl:

alkyl or (C6—C8) aryl, and NH—R11—OH Wherein R11 is
65

Particularly preferred are compounds Wherein the poly
mer P is poly-(x1[3-(N(2-hydroXyethyl)-D,L-asparagine), a

copolymer derived from poly(N-2-vinylpyrrolidone) or a

5,922,319
polysaccharide selected from the group consisting of

X3R15 is

deXtran, carboXyrnethyl cellulose, alginic acid and hydru
ronic acid.
Also preferred in Us. Pat. No. 5,162,307 are compounds
Wherein
A is selected from the group consisting of N-2

vinylpyrrolidone, N-hydroXypropylrnethacrylarnide,
2-hydroXyethyl rnethacrylate and acrylarnide,
B is selected from the group consisting of amino (C2—C6)

alkylrnethacrylarnide, arnino (C2—C6) alkylacrylarnide, 10
amino (C2—C6) alkyl rnaleic acid rnonoarnide, O-alkyl acry
A compound selected from the group consisting of a
late and rnethacrylate Where alkyl is of the general formula
compound
of the formula
CH2—CH(OH)—CH2—NH—R12—NH2 Where R12 is

C2—C6 hydrocarbon.
Even more preferred in the Us. Pat. No. 5,162,307 are 15

compounds Wherein
A and B are one and the same.

The most preferred and particular species of compounds
as stated in the Us. Pat. No. 5,162,307 are incorporated

herein by reference thereto.
Still other peptide or peptidyl carbarnate inhibitors of the

20

enzyme elastase Were disclosed in US. Pat. No. 5,008,245
to D1gen1s et al , WhlCh are useful In the present invention

and have the following structures

(III)
l
l

O :

MeO
O

P5

l
l

CH3

:

:

l
l

l
l

I

O I

l
l
l
l
l
l
l
l
l
l

l
l
l
l
l
l
l
l
l
l

|
l

P4

l

:

O

l
|

l
N

X3Rl5

|
|
|
|
|
|
|
|
|
|
|

l
|

P2

|

|

P1

|

I

wherein X is 1 or 2,
45

Y is carbobenZoXy or benZoyl, and
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5,922,319
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(46a) p-Nitrophenyl N-[Methoxysuccinyl-(Né
carbobenZoxy)-L-ornithyl-L-alanyl-L-prolylmethyl]-N
isopropylcarbamate
(46b) p-Nitrophenyl-(N6-carbobenZoxy)-L-ornithyl-L
alanyl-D-prolylmethyl]-N-isopropylcarbamate,
(47a) p-Nitrophenyl N-[Methoxysuccinyl-(N 6-benZoyl)-L
ornithyl-L-alanyl-L-prolylmethyl]-N-isopropylcarbamate,
(47b) p-Nitrophenyl N-[Methoxysuccinyl-(Né-benzoyl)-L
ornithyl-L-alanyl-D-prolylmethyl]-N isopropylcarbamate,
(48a) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N€
carbobenZoxy)-L-prolylmethyl]-N-isopropylcarbamate,
(48b) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N€
carbobenZoxy)-L-lysyl-D-prolylmethyl]-N
isopropylcarbamate,
(49a) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N€
benZoyl)-L-lysyl-L-prolylmethyl]-N-isopropylcarbamate,
(49b) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N€
benZoyl)-L-lysyl-D-prolylmethyl]-N-isopropylcarbamate,
(50a) p-Nitrophenyl N-[Methoxysuccinyl-L- alanyl-(Né
carbobenZoxy)-L-ornithyl-L-prolylmethyl]-N
isopropylcarbamate,
(50b) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N6
carbobenZoxy)-L-ornithyl-D-prolylmethyl]-N
isopropylcarbamate,
(5 1a) p-Nitrophenyl N-[Methoxysuccinyl-L- alanyl-(Né
benZoyl)-L-ornithyl-L-prolylmethyl]-N
isopropylcarbamate,
(51b) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N6
benZoyl)-L-ornithyl-D-prolylmethyl]-N
isopropylcarbamate,
(52) S-(1-phenyl-5-tetraZol) chloroformate,
(53) S-(1-phenyl-5-tetraZoyl)-N-[(N-Boc-L-prolyl)methyl]
N-isopropylthiocarbamate,
(54) S-(1 -phenyl-5-tetraZoyl-N-prolymethyl)-N
isopropylthiocarbamate hydrochloride,
(PC5) S-(1-phenyl-5-tetraZoyl)-N-[methoxysuccinyl
alanyl-(N€-CarbobenZoxy) lysyl prolyl methyl]-N

12
carboxymethyl cellulose, alginic acid and hyaluronic acid,
combinations thereof or combinations With other polymers.

Yet another example of suitable polymers With oxygen
atoms in the main polymer chain are polyether polymers,

examples of Which include polyethyleneglycol

(polyoxirane), divinylethermaleic acid copolymer (pyran
copolymer, DIVEMA), and the like. Examples of polymers
With a-CC-backbone suitable for use in this invention are

copolymers prepared from mixtures of different types of
10

monomers. One such group is a polymer formed by mixing
one type of monomer Which has active appended moieties
and another type of monomer lacking such moieties. Par

ticularly suitable are copolymers derived from hydrophilic
vinylic and/or acrylic type monomers. Examples include
15

N-2-vinylpyrrolidone, 2hydroxZypropylmethacrylamide,
2hydroxyethylmethacrylate and other hydrophilic esters and
amides of acrylic and methacrylic acid Which are Well
knoWn in the art. Suitable monomers containing appended
reactive moieties for preparation of copolymers for use in
this invention include, e.g., maleic acid anhydride and

reactive esters of acrylic and methacrylic acid. Particularly
suitable are, e.g., glycidyl acrylate, glycidyl methacrylate,

p-nitrophenyl, N-hydroxysuccinimide, pentachlorophenyl
or/and penta?uorophenyl esters of methacrylic and acrylic
25

acids, Wherein the alkoxy moiety of the reactive ester can be
either bound directly to the carbonyl of methacrylic or
acrylic acid or it can be bound via a spacer or linker.
Suitable spacers or linkers for use in these types of

polymers are generally knoWn in the art. Examples of

particularly suitable polymers include poly(N

vinylpyrrolidone), co-poly-(N-vinylpyrrolidone-co-maleic
acid anhydride), co-poly- (N-vinylpyrrolidone-co

methacryloyl-N-hydroxysuccinimide, co-poly(N-(2
hydroxypropyl)methacrylamide-co-methacryloyl
35

p-nitrophenyl ester) and other copolymers formed by the
monomers indicated above.

The polymers utiliZed for practicing the present invention

isopropyl-thiocarbamate, or

must be pharmaceutically-acceptable polymers. These are

(PC6) S-(1-phenyl-5-tetraZoyl)-N-[methoxysuccinyl-(N
carbobenZoyl)ornithylalanyl (prolylmethyl)-N

knoWn in the art as such.

isopropylthio carbamate.

polymer by means of a linker or spacer the linkers or spacers
must contain at least tWo reactive groups. One of the reactive

Where the HLE inhibitory agents are attached to the

Also suitable, however, are other polymer-bound HLE

inhibitory agents Which can be prepared by chemically
binding knoWn HLE inhibitory agents to someWhat hydro
philic and/or Water-soluble polymers as an artisan Would

groups must be capable of covalently bonding to the
45

knoW, and is for example described in US. Pat. No. 5,162,
307 to Digenis et al, described supra.
In general, the polymers suitable for use in this invention
are Water soluble polymers, and preferably, polymers having

appended moiety present in at least some of the monomer
units contained in the polymer. The other reactive group
must be capable of covalently bonding to a reactive group
present in the free HLE inhibitory agent molecule Which is
not involved in the binding to the active site of the enZyme.
Suitable linkers are knoWn in the art and need not be

a ?exible backbone structure Which are not easily biode

speci?cally described herein. One group of linkers Which

gradable and Which consequently have a prolonged biologi

has been found suitable for use With this invention is that

cal half life. Even more preferred are polymers Which are

encompassing ?exible backbone hydrocarbons containing at

Water soluble and substantially non-biodegradable but

least tWo reactive groups. Suitable are reactive groups such

as hydroxyl, sulfhydryl, amino, carboxyl, hydraZino and

Which also have a ?exible polymer backbone. A high ?ex

ibility exhibited by the polymer is helpful in increasing the
accessibility of the polymer bound inhibitory molecule to

55

hydroZido, among others. HoWever, other groups may also
be utiliZed. The length of the linker or spacer may vary as

the enZyme.
Suitable polymers for use in this invention are polymers

desired for particular applications. Typically, (C2—C2O)

containing amide bonds in the main chain. Particularly
useful are derivatives of synthetic polyamino acids,
examples of Which include random copolymers of 0t, [3

bons. HoWever, other types of molecules may also be

hydroxy alkyl-D,L-asp artamide, e.g., poly 0t, [3-(N-(2

found to be those comprising (C2—C20) hydrocarbons having

hydroxyethyl)-D,L-aspartamide) in Which a fraction of

covalently bonded substituents to the ?rst and last carbon
atoms such as hydroxylamines. Other examples suitable for

2-hydroxyethyl side-chains is replaced by appended reactive
moieties having HLE inhibitory activity.
Other examples of suitable polymers include polysaccha
ride derivatives, especially derivatives of dextran, cellulose,

hydrocarbon linkers are utiliZed, preferably linear hydrocar

incorporated herein.
Particularly suitable types of linker or spacer has been

65

use in this invention are 0t, -diamines, 0t, -diamino alcohols

and 0t, -diamino acids. By means of example, polymers With

multiple-bound HLE inhibitory agents provide an opportu

5,922,319
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nity to incorporate several inhibitory moieties into a single
unit, thereby increasing the ef?ciency of the transfer of the
inhibitory agent to the active site of the enZyme. This, in
turn, optimiZes the af?nity of the polymer-bound inhibitor
toWards the enZyme When compared With the loW-molecular

intervals are utiliZed as suitable for speci?c HLE inhibitory
agents and ocular conditions. Also part of this invention is
a method of reducing neovasculariZation of corneal scar
tissue or ?broblast proliferation comprising applying to an

Weight HLE inhibitory agent itself.

neovasculariZation-inhibitory amount of a human leukocyte
elastase (HLE) inhibitory agent under conditions and for a
period of time effective to attain the desired effect.
Typically, the application is conducted for a feW days to
up to a feW months, and sometimes for longer periods of

area of a subject’s eye afflicted With the condition a

The HLE inhibitory agents are prepared as is taught by the
art. By means of example, a group of derivatiZed oligopep

tides having HLE inhibitory activity may be prepared as
described in US. Pat. Nos. 4,643,991; 5,162,307; and 5,008,
245 all to Digenis et al.

10

time as needed to attain the desired result.

The loading of the HLE inhibitory agents onto the poly

As in the case of the prior method the HLE inhibitory
agent may be selected from the group consisting of free and

mers either alone or by means of a linker or spacer is

conducted by chemical reactions Which are knoWn in the art
and need not be described here in detail. The degree of

loading, i.e., density of the HLE inhibitory units along the

Water-soluble polymer-bound HLE inhibitory agents
15

The method described herein may also be practiced by
applying the inhibitory agent to corneal scarring or ?broblast

polymeric chain can be varied in a Way such that it is most

appropriate in accordance With the loading desired. This can

proliferation associated With post-operative conditions.

be attained by varying the experimental conditions, e.g., the
number of appended HLE active moieties on the polymeric
chain, the number of spacer groups and/or the ratio of HLE

Thus, the agent may be applied immediately after surgery, or
20

proliferation to Which the method is applied is associated

of these are shoWn in the examples of Us. Pat. No.
5,162,307 to Digenis et al. HoWever, other means can also

along the polymeric chain as is knoWn in the art.
In a preferred embodiment of the invention, the method is
practiced subsequent to an ocular operation, and the corneal
scarring or ?broblast proliferation is therefore post

With ocular conjunctivitis or other ocular infections or

biological damage. In this case, the corneal scarring is
25

produced by injury associated With microorganisms lodged
in the ocular cavity and/or tissues. The ocular composition
may in such cases additionally contain an antibiotic or other

operative. In another particular embodiment, the method of
the invention is applied to corneal scarring or ?broblast

as soon as ocular bleeding stops.

In another embodiment the corneal scarring or ?broblast

inhibitory groups to the polymer in the reaction. Examples

be utiliZed for adjusting the density of the inhibitory units

described above and/or knoWn in the art.

30

drug for the purpose of ?ghting the infection as Well. In
another embodiment, the method the invention may be
applied to corneal scarring or ?broblast proliferation Which

proliferation Which is associated With ocular conjunctivitis

is associated With corneal burning or heat-coagulation inju

or other ocular infections or biological damage.
In another embodiment of the invention the method is
applied to corneal scarring or ?broblast proliferation asso
ciated With corneal burning or other heat-associated damage
of the eye.
In still another embodiment, the method of the invention

ries.

In still another embodiment the method may be practiced
35

is applied to corneal scarring or ?broblast proliferation
Which is associated With mechanical injury or chemical

injury.

40

The method of the invention may be practiced by apply

on corneal scarring or ?broblast proliferation Which is
associated With mechanical injury of the eye, e.g., mechani
cal injury of the ocular cornea.
In still another embodiment the corneal scarring or ?bro

blast proliferation the method is applied to is associated With
chemical injury. This typically occurs by exposure of the
eye, and particularly the cornea, to chemical products Which
have a detrimental effect on ocular tissues.

In one embodiment of this method of the invention the

ing the HLE inhibitory agent topically, intraocularly, by
injection or through a contact lens. Preferred is topical

HLE inhibitory agent may be applied topically,

application.

intraocularly, by injection or through a contact lens. Pre
ferred is the topical application of an ocular composition,

Typically, the HLE inhibitory agent is applied as a com
position comprising an about 0.001—99.9 Wt. % aqueous
solution of the agent, preferably about 0.01—99 Wt. %
solution of the agent, and more preferably about 0.1—90 Wt.

45

e.g., a solution of the agent. By means of example a
composition comprising an aqueous solution of the com
pound may be applied to the eye as an about 0.001—99.9 Wt.

% solution thereof. Most preferably, the inhibitory agent is

% solution thereof, preferably about 0.01—99 Wt. %, and

applied in accordance With the present invention as a com

more preferably about 0.1—90 Wt. %. A most preferred

position comprising an aqueous solution containing about

50

be utiliZed. The composition may also contain other ingre
dients knoWn as useful in ocular treatments. These are
additives Which are knoWn in the art.

In still another embodiment of the invention the above
method may be applied as a preventative method to a subject

Who is susceptible to the ocular condition.
The HLE inhibitory agent may be applied to the eye of a
subject at varied intervals of time. Typically, the interval of
time Will depend on the residence time of the inhibitory

composition comprises a solution of the HLE inhibitory
agent of about 1—10 Wt. % thereof.
In still another embodiment, this method of the invention
is a preventative method Wherein the HLE inhibitory agent
is applied to a subject susceptible to the condition prior to its

1—10 Wt. % of the agent. Other amounts hoWever may also

55 occurrence.

Having noW generally described this invention, the same
Will be better understood by reference to certain speci?c

60

examples, Which are included herein for purposes of illus
tration only and are not intended to be limiting of the
invention or any embodiment thereof, unless so speci?ed.

agent in the eye. Thus, polymer-bound agents are “longer
acting” and need not be reapplied for longer periods of time

EXAMPLES

than free agents as is knoWn in the art. Typically, polymer
bound HLE inhibitory agents may be applied every about 24

Example 1: Chemicals and Solutions

periods of time. The free HLE inhibitory agents may be

The folloWing tWo representative compounds, KY7-11A
and KY-3-PC5, compounds A and B, respectively, Were

reapplied every about one hour to 24 hours. HoWever, other

tested for use in the methods of the invention.

hours to seven days, and in some instances even longer 65
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TABLE 1

Exemplary HLE Inhibitory Agents Utilized
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by a veterinarian (DVM) ophthalmologist (M.D.) under

Compound 1 is a peptidyl carbamate elastase (HLE)
inhibitor Which is chemically bound to a non-biodegradable
Water soluble polymer With an average molecular Weight of

aseptic conditions. Histopathology Was conducted by an
40

School of Medicine, Miami, Fla. and the Pathology Labo
ratory at the Ophthalmology Department at the University of
IoWa, IoWa City, IoWa.

about 1,000 to 5000,000 daltons. This compound is
described in US. Pat. No. 5,162,307. Compound 2 is a

peptidyl carbamate elastase (HLE) inhibitor and is repre
sentative of a large series of peptidyl carbamate HLE
inhibitors described in US. Pat. No. 5,008,245.
Example 2: Solutions Tested

All samples Were coded and all the above mentioned
45

Example 4: General Animal Preparation
26 rabbits Were tranquiliZed With acetylpromaZine

contains 1.4% W/V of polyvinyl alcohol. This solution Was
50

the corneas Were anesthetized, an eyelid speculum Was

This solution contains the active elastase inhibitory agent
(Compound 1 or Compound 2) at a concentration of 10
pg/mL. The inhibitory agent Was dissolved in normal saline

inserted and the lids Were then separated.
The corneas of each eye Were thermally coagulated With
55

(3) Solution C:
This solution contains the elastase inhibitory agent Com
pound 2 at a concentration of 50 pg/mL. This inhibitory
agent Was dissolved in normal saline (0.9% NaCl) contain

ing 1.4% W/v of polyvinyl alcohol.

60

All the above solutions Were freshly made immediately
prior to conducting the tests. The samples Were then kept
under refrigeration at 5° C.

Example 3: Animal Experiments
All surgery Was performed by a Board-certi?ed ophthal

mologist (M.D.). Sedation and euthanasia Were performed

maleate, 16 mg/kg intramuscularly. 2% lidocaine HCl eye
drops Were instilled in each eye for corneal anesthesia. Once

(2) Solution B:

(0.9% NaCl) containing 1.4% W/v of polyvinyl alcohol.

operators had no knowledge of the key to the code (blind

test).

(1) Solution A: Control
This solution consists of normal saline (0.9% NaCl) and
used as a control.

expert pathologist (MD) at the University of Miami,

the tip of a battery-powered ophthalmic cautery. A burn
measuring 3 mm in diameter Was placed near the superior
limbus of each eye.
TWo drops of solution A, B or C Were instilled in
designated treated eyes every 15 min for 6 hrs., then every
2 hrs. for 12 hrs. FolloWing this, tWo eye drops of the same
solutions Were instilled four times a day. Daily eye exami
nation Was performed and photographs Were taken.
TWo Weeks after treatment the rabbits Were sacri?ced by

longer intracardiac injection of T-61 (50 pmg/kg).
65

Subsequently, the rabbits, eyeballs Were enucleated, the

globes placed in Bounri’s solution (10% formalin solution)
and submitted for histopathology cell analysis.

5,922,319
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Example 5: Histopathological Results

leukocyte elastase (HLE) inhibitory agent under conditions
and for a period of time effective to attain a scar-reducing or

The eyes Were ?xed With 10% formalin solution and

?broblast proliferation-reducing effect;

labeled right (R) and left (L), as appropriate sectioned and
stained With H & E (hematoxylin & eosin stains). Histo

Wherein the HLE inhibitory agent is selected from the
group consisting of

logical sections Were read by a pathologist Without knoWl

(a) carbamates substituted by oligopeptides and described by
the folloWing general formula (I):

edge of the previously undertaken experimental procedure

(blind test).
Table 2 beloW shoWs typical results obtained from a
minimum of six (6) rabbits per treatment.

10

TABLE 2

R1

Microscopic Description of Rabbit Eyes
Treatment

Results

Untreated Solution A

Eyes (the untreated ones) showed an

(normal saline & 1.4%

area, 5-6 mm in extent, and involving
the entire thickness of the cornea, of
vascular and ?broblastic
proliferation With an intense

W/v polyvinyl alcohol)

in?ammatory in?ltrate consisting
predominantly of eosinophils, With
very feW plasma cells and lymphocytes.

15

consisting of straight or secondary branched-chain
20

?broblastic proliferation With
collagent deposition. In most of the

consisting of substituted or unsubstituted phenyl
Wherein the substituents are selected from the group
25

cases an intense stromal

vascularization With central scarring
and the presence of numerous

polymorphonuclear leukocytes, Were
Treated With Solution

B (10 ,ug/ml of
Compounds 1 or 2)

observed.
The reaction is not quite as intense
as in the untreated specimen. ToWard

alkyl of 1 to 4 carbon atoms, alkenyl of 1 to 4 carbon
atoms, alkynyl of 2 to 4 carbon atoms; and cycloalkyl
of 3 to 6 carbon atoms and R is selected from the group

In that area the surface epithelium
Was ulcerated. The deeper one half of
the cornea showed almost a pure

Wherein Z is selected from the group consisting of R“O-Suc
Wherein
R“ is loWer alkyl of 1 to 3 carbon atoms, and CF3CO—;
X is oxygen or sulfur; R‘ is selected from the group

30

consisting of nitro, ?uoro, benZyl, CH2CF2CF2CF3,
1-loWer alkyl tetraZolyl-, 1-phenyltetraZolyl-, 2-thioxo
3-thiaZolindyl, pyridyl, and benZothiaZolyl, provided
that When R is p-nitrophenyl, R‘ is other than tertiary
butyl, benZyl or cyclohexyl, and When X is sulfur, R is
other than benZyl;
(b) a polymer of the formula

the periphery of the specimen, of
corneal vascularization and migration
?broblasts into the cornea, Was or
observed. Centrally, there Was a Zone

35

of super?cial scarring, just beneath

Wherein
P is a polymer comprising at least one unit of the formula

the corneal epithelium.

(AmBn), Wherein (AmBn) are substantially nonbiodegradable

Super?cially, a Zone of proliferating
?broblasts around the carotid
collagen, Was also noticed.

polymer units and has an average molecular Weight of about

Treated With Solution

In contrast to the “untreated” eyes,

C (50 ,ug/ml Comp. B)

the treated eyes (With Solution C)

40

exhibited focal areas of subepithelial

covalently binding to one of L and R4;
Wherein R4 is selected from the group consisting of:
(i) a substituent C of the formula;

vascular proliferation of only 0.6
1.0 mm in extent and involved only one

third of the corneal thickness. This

represents a protection against
scarring, due to corneal burns of a

1,000 to 500,000 daltons, m and n may be the same or
different and are about 5 to 3,000, and A and B may be the
same or different and at least one of A and B is capable of

45

(C)

tenfold magnitude.
o

The above histopathologic results shoW that after appli
cation of the solutions (Solution A, B or C), severe ?brosis

50

and neovasculariZation Was still present in the control or
untreated corneas While very little neovasculariZation or

Wherein
X1 is oxygen or sulfur,

?brosis could be detected in the experimental corneas

(especially those treated With solution C). Accordingly,
ophthalmic solutions of Compound 1 or Compound 2, Which
are representative of a larger group of HLE inhibitory
agents, are proven effective in reducing ?brosis, neovascu
lariZation and in?ammation in corneal Wound-healing.
The invention noW being fully described, it Will be
apparent to one of ordinary skill in the art that many changes
and modi?cations can be made thereto Without departing

55

R5 is selected from the group consisting of straight and

secondary branch-chained (C1—C4) alkyl, (C2—C3)
alkenyl, (C2—C4) alkynyl, (C3—C6) cycloalkyl, and
benZyl,
R6 is selected from the group consisting of substituted and
60

unsubstituted phenyl, Wherein the substituents are

selected from the group consisting of nitro, penta?uoro,

benZyl, CH2CF2CF2CF3, 1-loWer alkyl tetraZolyl,
1-phenyltetraZolyl, 2-thioxo-3-thiaZolidinyl-, pyridyl

from the spirit or scope of the invention as set forth herein.
We claim:

ject’s eye afflicted With the condition a corneal scar-reducing

and benZothiaZolyl, provided that When R6 is
p-nitrophenyl, R5 is other than tert-butyl, benZyl or
cyclohexyl, and When X1 is sulfur, R6 is other than

or ?broblast proliferation-reducing amount of a human

benZyl;

1. A method of reducing corneal scarring or ?broblast
proliferation comprising administering to an area of a sub

65

5,922,319
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20
a compound of the formula

(ii) a substituent D of the formula

(D)

(IV)

wherein
X2 is O or S,

R8 is selected from the group consisting of phenyl,

nitrophenyl, ?uorophenyl, —CH2CF2CF2CF3, 1-loWer
alkyltetraZolyl, 1-phenyltetraZolyl, benZyl, 2-thioXo-3- 15
Wherein
thiaZolidinyl, pyridyl and benZothiaZolyl; and
R7 is selected from the group consisting of straight or

X 15 1 or 2;
Y is carbobenZoXy or benZoyl; and

secondary branch chained (C1—C4) alkyl, (C2—C3)
X3R15 in formulae (III) and (IV) is
alkenyl, (C2—C4) alkynyl, (C3—C6) cycloalkyl, and 20
benZyl, provided that When R8 is p-nitrophenyl, R7 is
other than tertiary-butyl, benZyl or cycloheXyl, and
When X2 is sulfur, R8 is other than benZyl; and
(iii) a substituent E of the formula

25

(E)

and P6, P5, P4, P3, P2, P1 and P1‘ de?ne regions of formulae

(III) and (IV).
30

2. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is post

operative.
3. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is associ
35

Wherein

Z2 is —O—Suc-Ala-Ala;
each said R4 being covalently bound to L or to one of A 40

and B,
L is selected from the group consisting of a covalent bond
and a linker group Which is covalently bound I0 R4 and
one ofA and B; and

45

q is about 1 to m+n; and

applied topically.
8. The method of claim 1, Wherein
the inhibitory agent is applied as an about 0.001 to 99.9%

(c) a compound selected from the group consisting of
50

aqueous solution.

9. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is post

a compound of the formula

operative.

(111)

55

6O
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and

ated With ocular infection.

4. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is associ
ated With corneal burning.
5. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is associ
ated With mechanical injury.
6. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is associ
ated With chemical injury.
7. The method of claim 1, Wherein the inhibitory agent is

10. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is associ
ated With ocular infection.
11. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is associ
ated With corneal burning.
12. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is associ
ated With mechanical injury.
13. The method of claim 1, Wherein
the corneal scarring or ?broblast proliferation is associ
ated With chemical injury.
14. A method of reducing neovasculariZation of corneal
scar tissue comprising administering to an area of a subj ect’s

5,922,319
21
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(ii) a substituent D of the formula;

eye a neovasculariZation-inhibitory amount of an HLE

inhibitory agent under conditions and for a period of time
effective sufficient to reduce neovasculariZation of corneal
scar tissue Wherein the HLE inhibitor agent is selected from

(D)
o

the group consisting of

(a) carbamates substituted by oligopeptides and described by
the following general formula (I):
10

Wherein
RI

X2 is O or S,

Wherein Z is selected from the group consisting of R“O-Suc
Where R“ is loWer alkyl of 1 to 3 carbon atoms, and
CF3CO—; X is oXygen or sulfur; R‘ is selected from the

15

R8 is selected from the group consisting of phenyl,

nitrophenyl, ?uorophenyl, —CH2CF2CF2CF3, 1-loWer
alkyltetraZolyl, 1-phenyltetraZolyl, benZyl, 2-thioXo-3
thiaZolidinyl, pyridyl and benZothiaZolyl, and

group consisting of straight or secondary branched-chain
alkyl of 1 to 4 carbon atoms, alkenyl of 1 to 4 carbon atoms,
alkynyl of 2 to 4 carbon atoms; and cycloalkyl of 3 to 6
carbon atoms, and R is selected from the group consisting of
substituted or unsubstituted phenyl Wherein the substituents
are selected from the group consisting of nitro, ?uoro,

benZyl, CH2CF2CF2CF3, 1-loWer alkyl tetraZolyl-,
1-phenyltetraZolyl-, 2-thioXo-3-thiaZolindyl, pyridyl, and

20

R7 is selected from the group consisting of straight or

secondary branch chained (C1—C4) alkyl, (C2—C3)
alkenyl, (C2—C4) alkynyl; and (C3—C6) cycloalkyl, and
benZyl, provided that When R8 is p-nitrophenyl, R7 is
other than tertiary-butyl, benZyl or cycloheXyl, and
When X2 is sulfur, R8 is other than benZyl; and

25

benZothiaZolyl, provided that When R is paranitrophenyl, R‘
is other than tertiary-butyl, benZyl or cycloheXyl, and When
X is sulfur, R is other than benZyl;
(b) a polymer of the formula

(iii) a substituent E of the formula

(E)
o

30

Wherein
P is a polymer comprising at least one unit of the formula

35

(AmBn), Wherein (AmBn) are substantially nonbiode
gradable polymer units and has an average molecular
Weight of about 1,000 to 500,000 daltons, m and n may
be the same or different and are about 5 to 3,000, and
A and B may be the same or different and at least one

Wherein
40

of A and B is capable of covalently binding to one of

Z2 is —O—Suc-Ala-Ala;

L and R4;

each said R4 being covalently bound to L or to one of A

Wherein R4 is selected from the group consisting of
(i) a substituent C of the formula:

and B,
45

(C)
o

L is selected from the group consisting of a covalent bond
and a linker group Which is covalently bound to R4 and
one ofA and B; and
q is about 1 to m+n; and
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(c) a compound selected from the group consisting of a
compound of the formula

Wherein
X1 is oxygen or sulfur;

R5 is selected from the group consisting of straight and

(111)
0
Me

O

benZyl, and
R6 is selected from the group consisting of substituted and
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selected from the group consisting of nitro, penta?uoro,

benZyl, CF2CF2CF2CF3, 1-loWer alkyl tetraZolyl,
1-phenyltetraZolyl, 2-thioXo-3-thiaZolidinyl-, pyridyl
and benZothiaZolyl, provided that When R6 is
p-nitrophenyl, R5 is other than tert-butyl, benZyl or
cycloheXyl, and When X1 is sulfur, R6 is other than

benZyl;

CH3
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secondary branch-chained (C1—C4) alkyl, (C2—C3)
alkenyl, (C2—C4) alkynyl; and (C3—C6) cycloalkyl, and
unsubstituted phenyl, Wherein the substituents are
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